Tissue penetration of antimicrobials: Difference between revisions
From IDWiki
(ββ) |
mNo edit summary Β |
||
(11 intermediate revisions by the same user not shown) | |||
Line 16: | Line 16: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" |β |
| style="text-align:center" |β |
||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
Line 24: | Line 24: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | + |
| style="text-align:center" | + |
||
| style="text-align:center" |Β± |
|||
|Β± |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
Line 31: | Line 31: | ||
|[[piperacillin-tazobactam]] |
|[[piperacillin-tazobactam]] |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" |β |
||
| style="text-align:center" |β |
|||
|β |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | +β |
| style="text-align:center" | +β |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
|- |
|- |
||
| rowspan=" |
| rowspan="6" |[[Cephalosporins]] |
||
|first-generation cephalosporins |
|first-generation cephalosporins |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" |β |
| style="text-align:center" |β |
||
| style="text-align:center" |β |
|||
|β |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
Line 49: | Line 49: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" |β |
| style="text-align:center" |β |
||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
Line 57: | Line 57: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" |Β± |
|||
|Β± |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | +β |
| style="text-align:center" | +β |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
|- |
|||
|[[ceftriaxone]] |
|||
| |
|||
| + |
|||
| |
|||
| |
|||
| |
|||
| |
|||
|- |
|- |
||
|[[cefepime]] |
|[[cefepime]] |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
Line 73: | Line 81: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | + |
| style="text-align:center" | + |
||
| style="text-align:center" |Β± |
|||
|Β± |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
Line 82: | Line 90: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" |β |
| style="text-align:center" |β |
||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
Line 90: | Line 98: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
Line 99: | Line 107: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
Line 105: | Line 113: | ||
|- |
|- |
||
|[[meropenem]] |
|[[meropenem]] |
||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" | + |
|||
| + |
|||
| style="text-align:center" | + |
|||
| + |
|||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" | + |
|||
| + |
|||
|- |
|- |
||
! colspan="8" |Antibiotics: Non-Ξ²-Lactams |
! colspan="8" |Antibiotics: Non-Ξ²-Lactams |
||
Line 118: | Line 126: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
Line 127: | Line 135: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | + |
| style="text-align:center" | + |
||
|- |
|- |
||
|[[Fluoroquinolones]] |
| rowspan="2" |[[Fluoroquinolones]] |
||
|all |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" |β? |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" |β? |
|||
| |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | + |
| style="text-align:center" | + |
||
| style="text-align:center" | + |
| style="text-align:center" | + |
||
|- |
|||
|[[moxifloxacin]] |
|||
| |
|||
| |
|||
| |
|||
|β |
|||
| |
|||
| |
|||
|- |
|- |
||
|[[Fosfomycin]] |
|[[Fosfomycin]] |
||
Line 145: | Line 161: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | + |
| style="text-align:center" | + |
||
Line 154: | Line 170: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" |β |
| style="text-align:center" |β |
||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
Line 161: | Line 177: | ||
|[[Lipopeptides]] |
|[[Lipopeptides]] |
||
|[[daptomycin]] |
|[[daptomycin]] |
||
| style="text-align:center" | + |
|||
| + |
|||
| style="text-align:center" |β |
|||
|β |
|||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" | + |
|||
| + |
|||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" | |
|||
| |
|||
|- |
|- |
||
|[[Macrolides]] |
|[[Macrolides]] |
||
Line 172: | Line 188: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" |β |
| style="text-align:center" |β |
||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | + |
| style="text-align:center" | + |
||
Line 181: | Line 197: | ||
| style="text-align:center" |β |
| style="text-align:center" |β |
||
| style="text-align:center" |β |
| style="text-align:center" |β |
||
| style="text-align:center" |β |
|||
| |
|||
| style="text-align:center" | + |
| style="text-align:center" | + |
||
| style="text-align:center" |β |
| style="text-align:center" |β |
||
Line 190: | Line 206: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
Line 197: | Line 213: | ||
|[[Oxazolidinones]] |
|[[Oxazolidinones]] |
||
|[[linezolid]] |
|[[linezolid]] |
||
| style="text-align:center" | + |
|||
| + |
|||
| style="text-align:center" | + |
|||
| + |
|||
| style="text-align:center" | + |
|||
| + |
|||
| style="text-align:center" |Β±β‘ |
|||
| |
|||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" | |
|||
| |
|||
|- |
|- |
||
|[[Rifamycins]] |
|[[Rifamycins]] |
||
Line 208: | Line 224: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | + |
| style="text-align:center" | + |
||
Line 217: | Line 233: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | + |
| style="text-align:center" | + |
||
Line 226: | Line 242: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" |β |
| style="text-align:center" |β |
||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | + |
| style="text-align:center" | + |
||
Line 234: | Line 250: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" |Β±[[CiteRef::jodlowski2020do]] |
|||
| style="text-align:center" | + |
| style="text-align:center" | + |
||
| style="text-align:center" | + |
| style="text-align:center" | + |
||
Line 243: | Line 259: | ||
| |
| |
||
|[[acyclovir]] / [[valacyclovir]] |
|[[acyclovir]] / [[valacyclovir]] |
||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" | + |
|||
| + |
|||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" | |
|||
| |
|||
|- |
|- |
||
| |
| |
||
|[[ganciclovir]] |
|[[ganciclovir]] |
||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" | + |
|||
| + |
|||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" | |
|||
| |
|||
|- |
|- |
||
| |
| |
||
|[[foscarnet]] |
|[[foscarnet]] |
||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" | |
|||
| |
|||
|- |
|- |
||
! colspan="8" |Antifungals |
! colspan="8" |Antifungals[[CiteRef::felton2014ti]] |
||
|- |
|- |
||
|[[Azoles]] |
| rowspan="3" |[[Azoles]] |
||
|[[fluconazole]] |
|[[fluconazole]] |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | + |
|||
| style="text-align:center" | + |
|||
| style="text-align:center" | + |
|||
| style="text-align:center" |Β± |
|||
| style="text-align:center" | + |
|||
|- |
|||
|[[itraconazole]] |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" |Β± |
|||
| + |
|||
| style="text-align:center" |β |
|||
| style="text-align:center" | + |
|||
| style="text-align:center" |β |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
|- |
|||
|[[voriconazole]] |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" |Β± |
|||
| style="text-align:center" |Β± |
|||
| style="text-align:center" |Β± |
|||
| style="text-align:center" | |
|||
| style="text-align:center" | |
|||
|- |
|||
| rowspan="3" |[[Echinocandins]] |
|||
|[[anidulafungin]] |
|||
| style="text-align:center" | + |
| style="text-align:center" | + |
||
| style="text-align:center" |Β± |
|||
| style="text-align:center" |β |
|||
| style="text-align:center" |Β± |
|||
| style="text-align:center" | |
|||
| style="text-align:center" | |
|||
|- |
|- |
||
|[[ |
|[[caspofungin]] |
||
| style="text-align:center" | + |
|||
| style="text-align:center" |β |
|||
| style="text-align:center" |β |
|||
| style="text-align:center" |Β± |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
|||
|- |
|||
|[[micafungin]] |
|||
| style="text-align:center" | |
|||
| style="text-align:center" |Β± |
|||
| style="text-align:center" |β |
|||
| style="text-align:center" |Β± |
|||
| style="text-align:center" | |
|||
| style="text-align:center" | |
|||
|- |
|||
| rowspan="2" |[[Polyenes]] |
|||
|deoxycholate [[amphotericin B]] |
|||
| style="text-align:center" | |
|||
| style="text-align:center" | |
|||
| style="text-align:center" |β |
|||
| style="text-align:center" | + |
| style="text-align:center" | + |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
|||
|β |
|||
|- |
|||
|liposomal [[amphotericin B]] |
|||
| style="text-align:center" | |
|||
| style="text-align:center" |β |
| style="text-align:center" |β |
||
| style="text-align:center" |Β±β |
|||
| style="text-align:center" | + |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
Line 299: | Line 364: | ||
*β if inflammation present |
*β if inflammation present |
||
*β‘ very low levels, but likely enough for [[Enterococcus]] |
|||
==Specific Tissues== |
==Specific Tissues== |
||
=== Central Nervous System === |
|||
* Reviewed in [[CiteRef::nau2010pe]] |
|||
{| class="wikitable" |
|||
!Class |
|||
!Antimicrobial |
|||
!CSF Penetration (AUC) |
|||
!With Meningeal Inflammation |
|||
|- |
|||
! colspan="4" |Antibiotics |
|||
|- |
|||
| rowspan="5" |[[penicillins]] |
|||
|overall |
|||
|2% |
|||
|2% |
|||
|- |
|||
|[[ampicillin]] |
|||
| |
|||
| |
|||
|- |
|||
|[[amoxicillin]] |
|||
| |
|||
|6% |
|||
|- |
|||
|[[cloxacillin]] |
|||
|0.87% |
|||
| |
|||
|- |
|||
|[[piperacillin]] |
|||
|3% |
|||
|32% |
|||
|- |
|||
| rowspan="3" |beta lactamase inhibitors |
|||
|overall |
|||
|7% |
|||
|10% |
|||
|- |
|||
|[[clavulanate]] |
|||
|4% |
|||
|8% |
|||
|- |
|||
|[[tazobactam]] |
|||
|11% |
|||
| |
|||
|- |
|||
| rowspan="4" |[[cephalosporins]] |
|||
|overall |
|||
|0.7 to 10% |
|||
|15% |
|||
|- |
|||
|[[cefotaxime]] |
|||
|12% |
|||
|4 to 17% |
|||
|- |
|||
|[[ceftriaxone]] |
|||
|0.7% |
|||
| |
|||
|- |
|||
|[[ceftazidime]] |
|||
|0.6% |
|||
| |
|||
|- |
|||
| rowspan="3" |[[carbapenems]] |
|||
|overall |
|||
|20% |
|||
|30% |
|||
|- |
|||
|imipenem |
|||
| |
|||
|14% |
|||
|- |
|||
|meropenem |
|||
|5 to 25% |
|||
|39% |
|||
|- |
|||
|[[aminoglycosides]] |
|||
|overall |
|||
|20% |
|||
| |
|||
|- |
|||
| rowspan="4" |[[fluoroquinolones]] |
|||
|overall |
|||
|30 to 70% |
|||
|70 to 90% |
|||
|- |
|||
|[[ciprofloxacin]] |
|||
|24 to 43% |
|||
|92% |
|||
|- |
|||
|[[levofloxacin]] |
|||
|71% |
|||
| |
|||
|- |
|||
|[[moxifloxacin]] |
|||
|46% |
|||
|79% |
|||
|- |
|||
|[[chloramphenicol]] |
|||
| |
|||
|60 to 70% |
|||
|60 to 70% |
|||
|- |
|||
|[[macrolides]] |
|||
|[[clarithromycin]] |
|||
| |
|||
|18% |
|||
|- |
|||
|[[tetracyclines]] |
|||
|[[doxycycline]] |
|||
|20% |
|||
|20% |
|||
|- |
|||
|[[fosfomycin]] |
|||
| |
|||
|18% |
|||
| |
|||
|- |
|||
|[[linezolid]] |
|||
|90% |
|||
| |
|||
| |
|||
|- |
|||
|[[metronidazole]] |
|||
| |
|||
| |
|||
|87% |
|||
|- |
|||
|[[rifamycins]] |
|||
|[[rifampin]] |
|||
|22% |
|||
| |
|||
|- |
|||
|[[trimethoprim-sulfamethoxazole]] |
|||
|[[trimethoprim]] |
|||
|18% |
|||
|42 to 51% |
|||
|- |
|||
| |
|||
|[[sulfamethoxazole]] |
|||
|12% |
|||
|24 to 30% |
|||
|- |
|||
|[[glycopeptides]] |
|||
|[[vancomycin]] |
|||
|14 to 18% |
|||
|30% |
|||
|- |
|||
|antituberculosis medications |
|||
|[[isoniazid]] |
|||
| |
|||
|86% |
|||
|- |
|||
! colspan="4" |Antivirls |
|||
|- |
|||
| rowspan="2" |anti-herpes nucleoside analogues |
|||
|[[acyclovir]] |
|||
|31% |
|||
| |
|||
|- |
|||
|[[valacyclovir]] |
|||
|19% |
|||
| |
|||
|- |
|||
|[[foscarnet]] |
|||
| |
|||
|27 to 43% |
|||
|23 to 66% |
|||
|- |
|||
| rowspan="4" |HIV antiretrovirals |
|||
|[[abacavir]] |
|||
|35% |
|||
| |
|||
|- |
|||
|[[zidovudine]] |
|||
|75% |
|||
| |
|||
|- |
|||
|[[indinavir]] |
|||
|6 to 15% |
|||
| |
|||
|- |
|||
|[[lopinavir]] |
|||
|29% |
|||
| |
|||
|- |
|||
! colspan="4" |Antifungals |
|||
|- |
|||
| |
|||
|[[flucytosine]] |
|||
| |
|||
|74% |
|||
|- |
|||
| rowspan="2" |[[azoles]] |
|||
|[[fluconazole]] |
|||
| |
|||
|86% |
|||
|- |
|||
|[[voriconazole]] |
|||
| |
|||
|46% |
|||
|- |
|||
|[[polyenes]] |
|||
|[[amphotericin B]] |
|||
| |
|||
|low |
|||
|- |
|||
! colspan="4" |Antiparasitics |
|||
|- |
|||
| |
|||
|[[albendazole]] |
|||
|38 to 43% |
|||
| |
|||
|- |
|||
| |
|||
|[[praziquantel]] |
|||
|24% |
|||
| |
|||
|- |
|||
| |
|||
|[[sulfadiazine]] |
|||
|27 to 33% |
|||
| |
|||
|} |
|||
===Prostate=== |
===Prostate=== |
||
Line 335: | Line 625: | ||
! colspan="5" |Antibiotics |
! colspan="5" |Antibiotics |
||
|- |
|- |
||
| rowspan="3" |penicillins |
| rowspan="3" |[[penicillins]] |
||
|[[ampicillin]] |
|[[ampicillin]] |
||
| |
| |
||
Line 351: | Line 641: | ||
|[[CiteRef::brockhaus2019re]] |
|[[CiteRef::brockhaus2019re]] |
||
|- |
|- |
||
| rowspan="4" |cephalosporins |
| rowspan="4" |[[cephalosporins]] |
||
|[[cefazolin]] |
|[[cefazolin]] |
||
| |
| |
||
Line 372: | Line 662: | ||
|[[CiteRef::brockhaus2019re]] |
|[[CiteRef::brockhaus2019re]] |
||
|- |
|- |
||
| rowspan="2" |carbapenems |
| rowspan="2" |[[carbapenems]] |
||
|[[imipenem]] |
|[[imipenem]] |
||
| |
| |
||
Line 383: | Line 673: | ||
|[[CiteRef::brockhaus2019re]] |
|[[CiteRef::brockhaus2019re]] |
||
|- |
|- |
||
|oxazolidinones |
|[[oxazolidinones]] |
||
|[[linezolid]] |
|[[linezolid]] |
||
| |
| |
||
Line 401: | Line 691: | ||
|[[CiteRef::brockhaus2019re]] |
|[[CiteRef::brockhaus2019re]] |
||
|- |
|- |
||
| rowspan="2" |aminoglycosides |
| rowspan="2" |[[aminoglycosides]] |
||
|[[amikacin]] |
|[[amikacin]] |
||
| |
| |
||
Line 412: | Line 702: | ||
|[[CiteRef::brockhaus2019re]] |
|[[CiteRef::brockhaus2019re]] |
||
|- |
|- |
||
| rowspan="3" |fluoroquinolones |
| rowspan="3" |[[fluoroquinolones]] |
||
|[[ciprofloxacin]] |
|[[ciprofloxacin]] |
||
| |
| |
||
Line 430: | Line 720: | ||
! colspan="5" |Antifungals |
! colspan="5" |Antifungals |
||
|- |
|- |
||
| rowspan="4" |azoles |
| rowspan="4" |[[azoles]] |
||
|[[fluconazole]] |
|[[fluconazole]] |
||
|40 to 50% |
|40 to 50% |
||
Line 457: | Line 747: | ||
|[[CiteRef::felton2014ti]] |
|[[CiteRef::felton2014ti]] |
||
|- |
|- |
||
|[[polyenes]] |
|||
| |
|||
|liposomal amphotericin B |
|liposomal amphotericin B |
||
| |
| |
||
Line 463: | Line 753: | ||
|[[CiteRef::felton2014ti]] |
|[[CiteRef::felton2014ti]] |
||
|- |
|- |
||
| rowspan="2" |echinocandins |
| rowspan="2" |[[echinocandins]] |
||
|echinocandins |
|echinocandins |
||
| |
| |
||
Line 473: | Line 763: | ||
|undetectable |
|undetectable |
||
|[[CiteRef::suzuki2008oc]][[CiteRef::felton2014ti]] |
|[[CiteRef::suzuki2008oc]][[CiteRef::felton2014ti]] |
||
|- |
|||
! colspan="5" |Antivirals |
|||
|- |
|||
| |
|||
|[[acyclovir]] |
|||
| |
|||
|above IC |
|||
| |
|||
|- |
|||
| |
|||
|[[valacyclovir]] |
|||
| |
|||
|20 to 30%, above IC in non-inflamed human eyes |
|||
|[[CiteRef::huynh2008vi]] |
|||
|- |
|||
| |
|||
|[[ganciclovir]] |
|||
| |
|||
|close to IC |
|||
| |
|||
|- |
|||
| |
|||
|[[foscarnet]] |
|||
|100% |
|||
|10%, close to IC |
|||
|[[CiteRef::lΓ³pez-cortΓ©s2000in]] |
|||
|} |
|} |
||
[[Category:Antimicrobials]] |
[[Category:Antimicrobials]] |
Latest revision as of 17:51, 19 September 2024
Summary
Class | Antimicrobial | Blood | CNS | Vitreous | Urine | Prostate | Necrotic |
---|---|---|---|---|---|---|---|
Antibiotics: Ξ²-Lactams | |||||||
Penicillins | Ξ²-lactamase inhibitors | β | |||||
ampicillin | + | Β± | β | ||||
piperacillin-tazobactam | β | β | +β | ||||
Cephalosporins | first-generation cephalosporins | β | β | β | |||
second-generation cephalosporins | β | ||||||
third-generation cephalosporins | Β± | +β | |||||
ceftriaxone | + | ||||||
cefepime | + | ||||||
ceftazidime | + | Β± | + | ||||
Cephamycins | cephamycins | β | |||||
cefoxitin | β | ||||||
Carbapenems | imipenem | + | |||||
meropenem | + | + | + | ||||
Antibiotics: Non-Ξ²-Lactams | |||||||
Aminoglycosides | β | ||||||
Chloramphenicol | chloramphenicol | + | |||||
Fluoroquinolones | all | β? | + | + | |||
moxifloxacin | β | ||||||
Fosfomycin | fosfomycin | + | |||||
Lincosamides | clindamycin | β | + | ||||
Lipopeptides | daptomycin | + | β | + | |||
Macrolides | macrolides | β | + | ||||
Nitrofurans | nitrofurantoin | β | β | β | + | β | β |
Nitroimidazoles | metronidazole | + | |||||
Oxazolidinones | linezolid | + | + | + | Β±β‘ | ||
Rifamycins | rifampin | + | |||||
Sulfonamides | trimethoprim-sulfamethoxazole | + | |||||
Tetracyclines | tetracyclines | β | + | ||||
doxycycline | Β±1 | + | + | ||||
Antivirals | |||||||
acyclovir / valacyclovir | + | ||||||
ganciclovir | + | ||||||
foscarnet | |||||||
Antifungals2 | |||||||
Azoles | fluconazole | + | + | + | Β± | + | |
itraconazole | Β± | β | + | β | |||
voriconazole | Β± | Β± | Β± | ||||
Echinocandins | anidulafungin | + | Β± | β | Β± | ||
caspofungin | + | β | β | Β± | |||
micafungin | Β± | β | Β± | ||||
Polyenes | deoxycholate amphotericin B | β | + | ||||
liposomal amphotericin B | β | Β±β | + | ||||
Class | Antimicrobial | Blood | CNS | Vitreous | Urine | Prostate | Necrotic |
- β if inflammation present
- β‘ very low levels, but likely enough for Enterococcus
Specific Tissues
Central Nervous System
- Reviewed in 3
Class | Antimicrobial | CSF Penetration (AUC) | With Meningeal Inflammation |
---|---|---|---|
Antibiotics | |||
penicillins | overall | 2% | 2% |
ampicillin | |||
amoxicillin | 6% | ||
cloxacillin | 0.87% | ||
piperacillin | 3% | 32% | |
beta lactamase inhibitors | overall | 7% | 10% |
clavulanate | 4% | 8% | |
tazobactam | 11% | ||
cephalosporins | overall | 0.7 to 10% | 15% |
cefotaxime | 12% | 4 to 17% | |
ceftriaxone | 0.7% | ||
ceftazidime | 0.6% | ||
carbapenems | overall | 20% | 30% |
imipenem | 14% | ||
meropenem | 5 to 25% | 39% | |
aminoglycosides | overall | 20% | |
fluoroquinolones | overall | 30 to 70% | 70 to 90% |
ciprofloxacin | 24 to 43% | 92% | |
levofloxacin | 71% | ||
moxifloxacin | 46% | 79% | |
chloramphenicol | 60 to 70% | 60 to 70% | |
macrolides | clarithromycin | 18% | |
tetracyclines | doxycycline | 20% | 20% |
fosfomycin | 18% | ||
linezolid | 90% | ||
metronidazole | 87% | ||
rifamycins | rifampin | 22% | |
trimethoprim-sulfamethoxazole | trimethoprim | 18% | 42 to 51% |
sulfamethoxazole | 12% | 24 to 30% | |
glycopeptides | vancomycin | 14 to 18% | 30% |
antituberculosis medications | isoniazid | 86% | |
Antivirls | |||
anti-herpes nucleoside analogues | acyclovir | 31% | |
valacyclovir | 19% | ||
foscarnet | 27 to 43% | 23 to 66% | |
HIV antiretrovirals | abacavir | 35% | |
zidovudine | 75% | ||
indinavir | 6 to 15% | ||
lopinavir | 29% | ||
Antifungals | |||
flucytosine | 74% | ||
azoles | fluconazole | 86% | |
voriconazole | 46% | ||
polyenes | amphotericin B | low | |
Antiparasitics | |||
albendazole | 38 to 43% | ||
praziquantel | 24% | ||
sulfadiazine | 27 to 33% |
Prostate
- Poorly penetrated by most antibiotics
- Penetration is higher with a high concentration gradient, high lipid solubility, low degree of ionization, high dissociation constant, low protein binding, and small molecular size
- Fluoroquinolones are the mainstay of therapy, though there is increasing resistance
- TMP-SMX often used, though conflicting data about its penetration into the prostate
- Minocycline, doxycycline, and macrolides achieve high levels in the prostate but are rarely indicated for the causative organisms
- Third-generation cephalosporins and carbapenems can be used
- Piperacillin, aztreonam, imipenem, and some aminoglycosides are likely useful
Bone
- Essentially all antibiotics achieve similar bone-to-serum levels, with the exception of oral Ξ²-lactams which nevertheless have no worse outcomes4
Eye
- Ocular compartments include anterior and posterior
- Anterior includes aqeous humour, and is best accessed using topical medications
- Posterior includes vitreous humour, retina, and choroid, and is best accessed using intravitreal or systemic medications
- Penetration of systemic antimicrobials into retina and vitreous is poor (~0 to 2%), but is better with inflammation5
- Preferred agents for vitreal penetration include meropenem, linezolid, and moxifloxacin
- Agents that are likely effective, especially when inflammation is present, include vancomycin, cefazolin, ceftriaxone, ceftazidime, imipenem, and trimethoprim-sulfamethoxazole, and possible daptomycin and rifampin
- Agents that do not reach adequate levels include ciprofloxacin, levofloxacin, aminoglycosides, aminopenicillins, piperacillin, cefepime, and clarithromycin
Class | Antimicrobial | Retinal Penetration | Vitreal Penetration | Ref |
---|---|---|---|---|
Antibiotics | ||||
penicillins | ampicillin | below MIC in non-inflamed rabbit eyes | 5 | |
amoxicillin | 2% (below MIC) in non-inflamed rabbit eyes | 5 | ||
piperacillin | undetectable in inflamed human eyes | 5 | ||
cephalosporins | cefazolin | above MIC in inflamed rabbit eyes | 5 | |
ceftriaxone | 4% in non-inflamed human eyes | 5 | ||
ceftazidime | 30% in inflamed rabbit eyes | 5 | ||
cefipime | 8% in non-inflamed human eyes | 5 | ||
carbapenems | imipenem | 8 to 10% in non-inflamed human eyes | 5 | |
meropenem | 30% in non-inflamed human eyes | 5 | ||
oxazolidinones | linezolid | 30 to 80% in non-inflamed human eyes | 5 | |
vancomycin | above MIC in inflamed rabbit eyes | 5 | ||
daptomycin | 30% in inflamed human eyes | 5 | ||
aminoglycosides | amikacin | below MIC in inflamed rabbit eyes | 5 | |
gentamicin | below MIC in inflamed rabbit eyes | 5 | ||
fluoroquinolones | ciprofloxacin | below MIC in non-inflamed human eyes | 5 | |
levofloxacin | 30% but below MIC in non-inflamed human eyes | 5 | ||
moxifloxacin | 10 to 40% and above MIC in non-inflamed human eyes | 5 | ||
Antifungals | ||||
azoles | fluconazole | 40 to 50% | 40 to 50% | 62 |
itraconazole | 10% in inflamed eyes | 2 | ||
posaconazole | 20% in inflamed eyes | 2 | ||
voriconazole | 40 to 100% | 2 | ||
flucytosine | 40 to 100% | 2 | ||
polyenes | liposomal amphotericin B | only detectable in inflamed eyes | 2 | |
echinocandins | echinocandins | very low penetration | 2 | |
micafungin | excellent | undetectable | 62 | |
Antivirals | ||||
acyclovir | above IC | |||
valacyclovir | 20 to 30%, above IC in non-inflamed human eyes | 7 | ||
ganciclovir | close to IC | |||
foscarnet | 100% | 10%, close to IC | 8 |
References
- ^ Tomasz Jodlowski, Charles R Ashby, Sarath G Nath. Doxycycline for ESBL-E Cystitis. Clinical Infectious Diseases. 2020. doi:10.1093/cid/ciaa1898.
- a b c d e f g h i Timothy Felton, Peter F. Troke, William W. Hope. Tissue Penetration of Antifungal Agents. Clinical Microbiology Reviews. 2014;27(1):68-88. doi:10.1128/cmr.00046-13.
- ^ nau2010pe
- ^ Cornelia B. Landersdorfer, JΓΌrgen B. Bulitta, Martina Kinzig, Ulrike Holzgrabe, Fritz SΓΆrgel. Penetration of Antibacterials into Bone. Clinical Pharmacokinetics. 2009;48(2):89-124. doi:10.2165/00003088-200948020-00002.
- a b c d e f g h i j k l m n o p q r L. Brockhaus, D. Goldblum, L. Eggenschwiler, S. Zimmerli, C. Marzolini. Revisiting systemic treatment of bacterial endophthalmitis: a review of intravitreal penetration of systemic antibiotics. Clinical Microbiology and Infection. 2019;25(11):1364-1369. doi:10.1016/j.cmi.2019.01.017.
- a b Takashi Suzuki, Toshihiko Uno, Guangming Chen, Yuichi Ohashi. Ocular distribution of intravenously administered micafungin in rabbits. Journal of Infection and Chemotherapy. 2008;14(3):204-207. doi:10.1007/s10156-008-0612-5.
- ^ Tony H. Huynh, Mark W. Johnson, Grant M. Comer, Douglas N. Fish. Vitreous Penetration of Orally Administered Valacyclovir. American Journal of Ophthalmology. 2008;145(4):682-686. doi:10.1016/j.ajo.2007.11.016.
- ^ Luis F. LΓ³pez-CortΓ©s, R. Ruiz-Valderas, M. J. Lucero-MuΓ±oz, E. Cordero, M. T. Pastor-Ramos, J. Marquez. Intravitreal, Retinal, and Central Nervous System Foscarnet Concentrations after Rapid Intravenous Administration to Rabbits. Antimicrobial Agents and Chemotherapy. 2000;44(3):756-759. doi:10.1128/aac.44.3.756-759.2000.